课题基金 / 基金详情

Human Enterohepatic Cell Model for Predictive Toxicology

Human Enterohepatic Cell Model for Predictive Toxicology
用于预测毒理学的人类肠肝细胞模型
批准号:
7459078
负责人:
Jeffrey M. Macdonald
金额:
$33.12万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-07-01 至 2010-06-30

项目摘要

项目成果

Jeffrey M. Macdonald的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供): 将一种候选药物推向市场需要花费5000亿美元。这笔费用导致制药公司将重点放在最具盈利潜力的化合物上,忽视了收入预期较低的急需药物的开发,并将高昂的研究成本转嫁给消费者。所有这些行业趋势都显著增加了因无法获得或负担不起所需药物而无法获得所需药物的患者数量。制药业正试图通过大量投资于人类临床前研究来解决这一问题,以此作为控制成本和提高药物开发成功的机制。该行业迫切需要新的工具来支持人类临床前研究计划。尤其需要先进的体外模型系统来评估化学品和药物的毒性。本项目的目标就是开发这样一个系统。 摘要: 目前用于测试候选药物的体外技术是基于40年前开发的二维(2-D)三明治肝细胞培养技术。这些体内模型由于组织和生物体水平上生化途径的结构和功能的异质性而变得复杂,并且不允许清楚地定义或可重复地检查机制。需要一个体外系统,它是一个更好的人类肝脏模型。在过去的十几年里,这个研究团队一直在开发一种最先进的多同轴生物反应器(MCB),以创造第一个人类生物人工肝。在过去的四年里,该团队一直专注于确定用于种植三维(3-D)生物反应器培养的最佳人类肝细胞群。已经确定,含有肝干/祖细胞的未分离的人肝细胞混合物提供了良好的生物反应器结果。除了这项工作外,该团队还开发了多功能的核磁共振兼容生物反应器,可以获得原位代谢组学和通量组学数据。 在本项目中,我们将创建第一个三维人体生物人工肠-肝器官系统,并建立该模型系统用于评估化学品和药物毒性的可行性。这项拟议的技术将基于将一定数量的人类肝细胞整合到细胞外基质中,从而创造一个由不溶因素的精确组成的微环境,以与细胞相互作用。被包裹的肝细胞将被放置在一个生物反应器舱中,该舱毗邻一个装有人类衍生肠道细胞系Caco-2的舱。这将使用两种多隔室生物反应器设计来实现;一个是多同轴生物反应器(MCB),另一个是核磁共振兼容生物反应器。拟议的生物反应器设计至少包含4个隔间。这将允许两种类型的细胞在一个很小的空间内相互作用,并由代表血液和肠室的单独的血浆/肠室进行灌流。这将模仿人类肠道-肝脏系统的血液流动。MCB生物反应器的优点是更好地复制了肠道屏障。核磁共振兼容生物反应器的优点在于,一种新的交错核磁共振方法可以同时从两个组织中获得原位代谢组和流动组数据。该项目的预期结果将是一个人造人体肝脏模型,将用于计算代谢和流动组学分析,以确定毒理学和药理学的药物靶标。
英文摘要
DESCRIPTION (provided by applicant): It costs half a trillion dollars to bring a drug candidate to market. This expense is causing pharmaceutical companies to focus on compounds that have the greatest earning potential, orphan the development of critically needed drugs that have low revenue projections, and transfer high research costs to the consumer. All of these industry trends significantly increase the number of patients who can not access needed medicine because it is unavailable or unaffordable. The pharmaceutical industry is attempting to address this problem by heavily investing in human pre-clinical research as a mechanism to control cost and enhance the success of drug development. The industry is anxious for new tools to support the human pre-clinical research initiative. There is a particular need for advanced in vitro model systems to evaluate the toxicity of chemicals and drugs. This project's goal is to develop such a system. Abstract: The current in vitro technology for testing drug candidates is based on two-dimensional (2-D) sandwich livercell culturing techniques developed four decades ago. These In vivo models are complicated by the presence of structural and functional heterogeneity of biochemical pathways at the tissue and organism levels, and do not allow for mechanisms to be clearly defined or reproducibly examined. An in vitro system that is a much better model of a human liver is needed. Over the past dozen years this research team has been developing a state-of-the-art multicoaxial bioreactor (MCB) for creating the first human bioartificial liver. Over the past four years the team has focused on identifying the optimum human liver cell population for seeding the three-dimensional (3-D) bioreactor cultures. It has been determined that an unfractionated mixture of human liver cells shown to contain hepatic stem/progenitors provides favorable bioreactor results. In addition to this work the team has developed versatile NMR-compatible bioreactors that can obtain in situ metabolomics and fluxomics data. In this project we will create the first 3-D human bioartificial entero-hepatic organ-system and establish the feasibility of using this model system to evaluate the toxicity of chemicals and drugs. The proposed technology will be based on incorporating a defined population of human liver cells in an extracellular matrix thus creating a microenvironment composed of a precise composition of insoluble factors to interact with the cells. The encapsulated hepatocytes will be placed in a bioreactor compartment adjacent to a compartment containing a human derived- intestinal cell line, CaCo-2. This will be achieved using two multiple compartment bioreactor designs; a multicoaxial bioreactor (MCB) and a NMR-compatible bioreactor. The proposed bioreactor designs contain at least 4 compartments. This will permit the two cell types to interact across a small space and be perfused by separate plasma/intestinal compartments representing the blood and the intestinal compartments. This will mimic blood flow of the human entero-hepatic system. The advantage of the MCB bioreactor is that the intestinal barrier is better replicated. The advantage of the NMR-compatible bioreactor is that a novel interleaved NMR method can obtain in situ metabolomic and fluxomic data simultaneously from the two tissues. The expected result of this project will be an artificial human liver model that will be used with computational metabolomic and fluxomic analysis to identify toxicological and pharmacological drug targets.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
Lyn regulates creatine uptake in an imatinib-resistant CML cell line.
Lyn 调节伊马替尼耐药 CML 细胞系中肌酸的摄取。
DOI: 10.1016/j.bbagen.2019.129507
发表时间: 2020
期刊: Biochimica et biophysica acta. General subjects
影响因子: --
作者: [Okumu,DenisO, Aponte-Collazo,LucasJ, Dewar,BrianJ, Cox,NathanJ, East,MichaelP, Tech,Katherine, McDonald,IanM, Tikunov,AndreyP, Holmuhamedov,Ekhson, Macdonald,JeffreyM, Graves,LeeM]
通讯作者: Graves,LeeM
¹³C magnetic resonance spectroscopy detection of changes in serine isotopomers reflects changes in mitochondrial redox status.
13C磁共振波谱检测丝氨酸同位素的变化反映了线粒体氧化还原状态的变化。
DOI: 10.1002/mrm.23296
发表时间: 2012
期刊: Magnetic resonance in medicine
影响因子: 3.3
作者: [Johnson,CBryce, Tikunov,AndreyP, Lee,Haakil, Wolak,JustynaE, Pediaditakis,Peter, Romney,DougA, Holmuhamedov,Ekhson, Gamcsik,MichaelP, Macdonald,JeffreyM]
通讯作者: Macdonald,JeffreyM
DOI: 10.3390/ijms23094733
发表时间: 2022-04-25
期刊: International journal of molecular sciences
影响因子: 5.6
作者: []
通讯作者:
Human Enterohepatic Cell Model for Predictive Toxicology
  • 批准号:
    7268038
  • 项目类别:
  • 资助金额:
    $33.76万
  • 财政年份:
    2006
  • 负责人:
    Jeffrey M. Macdonald
  • 依托单位:
Human Enterohepatic Cell Model for Predictive Toxicology
  • 批准号:
    7012944
  • 项目类别:
  • 资助金额:
    $34.77万
  • 财政年份:
    2006
  • 负责人:
    Jeffrey M. Macdonald
  • 依托单位:
DETERMINAT OF RADIAL FLOW BY MR MICROSCOPY IN COAXIAL BIOARTIFICIAL LIVER LOBULE
  • 批准号:
    6493747
  • 项目类别:
  • 资助金额:
    $28.8万
  • 财政年份:
    2001
  • 负责人:
    Jeffrey M. Macdonald
  • 依托单位:
DETERMINAT OF RADIAL FLOW BY MR MICROSCOPY IN COAXIAL BIOARTIFICIAL LIVER LOBULE
  • 批准号:
    6348180
  • 项目类别:
  • 资助金额:
    $0.38万
  • 财政年份:
    2000
  • 负责人:
    Jeffrey M. Macdonald
  • 依托单位:
海外基金